Dates: March 17-21, 2026
Location: Copenhagen, Denmark
Organizer: Kenes Group
Overview
flowchart TD
events_adpd_2026_posters_abstr["AD/PD 2026 Poster and Abstract Highlights"]
events_adpd_2026_posters_abstr["Dates"]
events_adpd_2026_posters_abstr -->|"related to"| events_adpd_2026_posters_abstr
style events_adpd_2026_posters_abstr fill:#81c784,stroke:#333,color:#000
events_adpd_2026_posters_abstr["March"]
events_adpd_2026_posters_abstr -->|"related to"| events_adpd_2026_posters_abstr
style events_adpd_2026_posters_abstr fill:#81c784,stroke:#333,color:#000
events_adpd_2026_posters_abstr["Location"]
events_adpd_2026_posters_abstr -->|"related to"| events_adpd_2026_posters_abstr
style events_adpd_2026_posters_abstr fill:#81c784,stroke:#333,color:#000
events_adpd_2026_posters_abstr["Copenhagen"]
events_adpd_2026_posters_abstr -->|"related to"| events_adpd_2026_posters_abstr
style events_adpd_2026_posters_abstr fill:#81c784,stroke:#333,color:#000
style events_adpd_2026_posters_abstr fill:#4fc3f7,stroke:#333,color:#000
The poster and abstract sessions at AD/PD 2026 featured hundreds of presentations from researchers worldwide, showcasing the latest findings in basic science, clinical research, and therapeutic development for Alzheimer's and Parkinson's diseases["@adpd2026"][@chen2023].
Alzheimer's Disease Abstracts
Amyloid and APP Biology
Novel Mechanisms ... Dates: March 17-21, 2026
Location: Copenhagen, Denmark
Organizer: Kenes Group
Overview
Mermaid diagram (expand to render)
The poster and abstract sessions at AD/PD 2026 featured hundreds of presentations from researchers worldwide, showcasing the latest findings in basic science, clinical research, and therapeutic development for Alzheimer's and Parkinson's diseases["@adpd2026"][@chen2023].
Alzheimer's Disease Abstracts
Amyloid and APP Biology
Novel Mechanisms
APP processing variants: Rare genetic variants affecting amyloid generationAlpha-secretase regulation: New insights into ADAM10/ADAM17 activityAmyloid oligomer toxicity: Cell-based models of amyloid speciesAPOE4 effects: Mechanisms of APOE4-mediated riskTherapeutic Approaches
Antibody engineering: Next-generation anti-amyloid antibodiesBACE inhibitor alternatives: Novel gamma-secretase modulatorsSmall molecule aggregators: Anti-aggregation compound screeningCombination strategies: Multi-target approach developmentTau Pathology and Therapeutics
Basic Science
Tau post-translational modifications: Acetylation, methylation, and truncationTau propagation mechanisms: Cell-to-cell transmission pathwaysTau isoforms: Differential toxicity of 3R and 4R tauTau PET correlations: Imaging-pathology correlationsClinical
Tau PET longitudinal studies: Disease progression markersAnti-tau antibody results: Safety and efficacy dataTau aggregation inhibitors: Phase 1/2 resultsBiomarker correlations: Fluid and imaging biomarkersNeuroinflammation
Microglial Biology
[TREM2](/proteins/trem2) biology: Agonist and antagonist approachesDAM pathway: Disease-associated microglia phenotypesMicroglial priming: Age-related activation changesCX3CR1 modulation: Fractalkine receptor targetingComplement System
C1q inhibition: Synaptic protection approachesC3 therapeutics: Complement-mediated inflammationMicroglia-neuron crosstalk: Synaptic maintenance mechanismsBiomarkers and Diagnostics
Fluid Biomarkers
p-tau217: Clinical utility and standardizationp-tau181: Cross-platform validationNfL: Neurodegeneration monitoringNeurogranin: Synaptic damage markersNovel Approaches
Extracellular vesicles: Biomarker cargoMultiplex platforms: Multi-analyte panelsPoint-of-care tests: Rapid diagnosticsParkinson's Disease Abstracts
Alpha-Synuclein Research
Basic Mechanisms
Aggregation kinetics: Seed amplification studiesOligomer species: Toxic intermediate characterizationPropagation pathways: Prion-like spread mechanismsLewy body composition: Structural analysisTherapeutics
Immunotherapy approaches: Active and passive immunizationSmall molecule inhibitors: Aggregation blockersGene therapy: SNCA targeting strategiesCell therapy: Dopaminergic cell replacementGenetic Subtypes
LRRK2
LRRK2 biology: Kinase function and regulationInhibitor development: Clinical candidate updatesBiomarker development: pS935-LRRK2 as PD markerGenetic stratification: Patient selection for trialsGBA
GBA mutations: Frequency and phenotypic effectsGaucher-PD connection: Mechanism of riskSubstrate reduction: Therapeutic approachesEnzyme enhancement: Pharmacological chaperonesMitochondrial Dysfunction
Mitophagy Pathways
[PINK1](/genes/pink1)/[Parkin](/genes/parkin): Mitophagy initiation mechanismsMFN1/2: Mitochondrial fusion dynamicsParkinsonism models: Genetic and toxin-basedTherapeutic targets: Enhancing mitophagyComplex I deficiency: Electron transport chainCoQ10 approaches: Mitochondrial supplementationMetabolic enhancers: ATP production supportMotor and Non-Motor Symptoms
Motor Complications
Dyskinesia mechanisms: L-DOPA-induced movementsContinuous delivery: LCIG and pump therapiesDevice-based treatments: Deep brain stimulationNon-Motor Symptoms
Sleep disorders: REM sleep behavior disorderCognitive impairment: Dementia in PDAutonomic dysfunction: Gastrointestinal issuesCross-Disease Themes
Common Mechanisms
Protein Aggregation
Prion-like spread: Common mechanisms across diseasesStrain variation: Disease-specific aggregatesSeeding assays: Cross-diagnostic applicationsNeuroinflammation
Microglial activation: Shared pathwaysComplement involvement: Synaptic loss mechanismsPeripheral immunity: Systemic-brain connectionsBiomarker Convergence
p-tau in PD: Alzheimer's biomarkers in Parkinson'sAlpha-synuclein in AD: Lewy body pathology in ADNfL: 通用 neurodegeneration markerAwards and Recognitions
Young Investigator Awards
Best Basic Science Abstract: Protein aggregation mechanismsBest Clinical Abstract: Biomarker-driven trial designBest Translational Abstract: Therapeutic developmentTravel Grants Supported by:
Movement Disorder Society
Alzheimer's Association
Industry sponsors
Poster Session Highlights
Day 1: Amyloid and Basic Mechanisms Featured posters on:
APP processing and trafficking
Amyloid generation and clearance
Synaptic dysfunction
Day 2: Tau and Neuroinflammation Featured posters on:
Tau post-translational modifications
Microglial activation states
[Complement system](/entities/complement-system)
Day 3: Alpha-Synuclein and Genetics Featured posters on:
Seed amplification assays
LRRK2 biology
GBA-associated PD
Day 4: Biomarkers and Diagnostics Featured posters on:
Fluid biomarker development
PET tracer advancement
Clinical diagnostics
Day 5: Clinical Trials and Therapeutics Featured posters on:
Anti-amyloid trial results
Anti-tau therapeutic approaches
Gene and cell therapy
Key Takeaways
Basic science advancing — Novel mechanisms being characterizedBiomarker standardization — Fluid biomarker validation progressingTherapeutic diversity — Multiple modalities in developmentGenetic stratification — Precision medicine approaches emergingCross-disease insights — Common mechanisms explored
See Also
[AD/PD 2026 Conference](/events/adpd-2026)](/events)
[AD/PD 2026 Scientific Sessions](/events/adpd-2026-scientific-sessions)](/events)
[AD/PD 2026 Plenary Sessions](/events/adpd-2026-plenary-sessions)](/events)
[AD/PD 2026 Clinical Trial Updates](/events/adpd-2026-clinical-trials)](/events)
[Events Index](/events/conference-index)
References
Unknown, AD/PD 2026 Conference Website (2026)
[Chen Y, et al., Integrated approach to neurodegenerative disease research. Nat Rev Neurosci. 2023 (2023)](https://doi.org/10.1038/s41583-023-00656-2) Show full description